JNJ Nears 52-Week Peak Amid Legal Win and Promising Heart Device Data
Johnson & Johnson shares approach a 52-week high after a New Jersey court disqualified a plaintiffs' firm from talc cases and the company released positive pilot data for its experimental atrial fibrillation platform.
Markets
Feb 8
